Long-acting formulation of a new muscarinic receptor antagonist for the treatment of overactive bladder

Journal of Microencapsulation

Volumn 30, Issue 2, 2013, Pages 116-123

  Teng, Lesheng ^a,b   Jiang, Chaojun ^a   Sun, Fengying ^a   Li, Chunmei ^a   Teng, Lirong ^a   Meng, Qingfan ^a   Lee, Robert J ^a,b   Li, Youxin ^a  

^a JILIN UNIVERSITY   (China)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

5 hydroxymethyl tolterodine; Biodegradable polymer; Microsphere; Pharmacodynamics; Pharmacokinetics

Indexed keywords

CARBACHOL; MICROSPHERE; POLYGLACTIN; TOLTERODINE;

ANIMAL MODEL; ARTICLE; BLADDER; CONCENTRATION (PARAMETERS); DIFFERENTIAL SCANNING CALORIMETRY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG RELEASE; EXPERIMENTAL DOG; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MICROENCAPSULATION; MICTURITION; NONHUMAN; OVERACTIVE BLADDER; PARTICLE SIZE; RAT; TIME; X RAY POWDER DIFFRACTION;

ANIMALS; ANTIMICROBIAL CATIONIC PEPTIDES; BENZHYDRYL COMPOUNDS; CAPSULES; CRESOLS; DELAYED-ACTION PREPARATIONS; FEMALE; MICROSPHERES; MUSCARINIC ANTAGONISTS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, MUSCARINIC; URINARY BLADDER, OVERACTIVE;

EID: 84873047884     PISSN: 02652048     EISSN: 14645246     Source Type: Journal    
DOI: 10.3109/02652048.2012.704950     Document Type: Article

References (24)

1. Abrams P, Freeman R, Anderstrom C, Mattiasson A. Tolterodine, a new antimuscarinic agent: As effective but better tolerated than oxybutynin in patients with an overactive bladder. Br J Urol, 1998;81:801-10.
2. Appell RA. Clinical efficacy and safety of tolterodine in the treatment of overactive bladder: A pooled analysis. Urology, 1997;50:90-6.
3. Chu DF, Tian JW, Liu WH, Li Z, Li YX. Poly(lactic-co-glycolic acid)microspheres for the controlled release of huperzine A: In vitro and in vivo studies and the application in the treatment of the impaired memory of mice. Chem Pharm Bull, 2007;55:625-8.
4. Du L, Cheng JP, Chi Q, Qie JK, Liu Y, Mei XG. Biodegradable PLGA microspheres as a sustained release system for a new luteinizing hormonereleasing hormone (LHRH) antagonist. Chem Pharm Bull, 2006;54:1259-65.
5. FDA. 1997. Guidance for industry: Dissolution testing of immediate release solid oral dosage forms. Silver Spring, MD: Center for Drug Evaluation and Research, USA, p. 9.
6. Freitas S, Merkle HP, Gander BJ. Microencapsulation by solvent extraction/evaporation: Reviewing the state of the art of microsphere preparation process technology. J Control Release, 2005;102:313-32.
7. Gasparini G, Kosvintsev SR, Stillwell MT, Holdich RG. Preparation and characterization of PLGA particles for subcutaneous controlled drug release by membrane emulsification. Colloids Surf B, 2008;61:199-207.
8. Izumikawa S, Yoshioka S, Aso Y, Takeda Y. Preparation of poly (l-lactide) microspheres of different crystalline morphology and effect of crystalline morphology on drug release rate. J Controlled Release, 1991;15:133-40.
9. Jacobsen LO, Kreilgard B, Hoeck U, Kristensen H. 2003. Transdermally administered tolterodine as anti-muscarinic agent for the treatment of overactive bladder, US Patent 6,517,864.
10. Jiang CJ, Teng LS, Teng LR, Li CM, Li YX. Biodegradable PLGA microsphere for the controlled release of tolterodine derivative. J Biotechnol, 2008;136:S416-7.
11. Kerrebroeck PV, Kreder K, Jonas U, Zinner N, Wein AN. Tolterodine oncedaily: Superior efficacy and tolerability in the treatment of the overactive bladder. Urology, 2001;57:414-21.
12. Knox ED, Stimmel GL. Clinical review of a long-acting, injectable formulation of risperidone. Clin Ther, 2004;26:1994-2002.
13. Liu WH, Song JL, Liu K, Chu DF, Li YX. Preparation and in vitro and in vivo release studies of Huperzine A loaded microspheres for the treatment of Alzheimer's disease. J Control Release, 2005;107:417-27.
14. Mao SR, Xu J, Cai CF. Effect of WOW process parameters on morphology and burst release of FITC-dextran loaded PLGA microspheres. Int J Pharm, 2007;334:137-48.
15. Nahata T, Saini TR. Optimization of formulation variables for the development of long acting microsphere based depot injection of olanzapine. J Microencapsul, 2008;25:426-33.
16. Nilvebrant L, Hallen B, Larsson G. Tolterodine, a new bladder selective muscarinic receptor antagonist: Preclinical pharmacological and clinical data. Life Sci, 1997;60:1129-36.
17. Okada H, Toguchi H. Biodegradable microspheres in drug delivery. Crit Rev Ther Drug, 1995;12:1-99.
18. Pahlman Z, Gozzi P. Serum protein binding of tolterodine and its major metabolites in humans and several animal species. Biopharm Drug Dispos, 1999;20:91-9.
19. Patel P, Mundargi RC, Babu VR, Jain D, Rangaswamy V, Aminabhavi TM. Microencapsulation of doxycycline into poly(lactide-co-glycolide) by spray drying technique: Effect of polymer molecular weight on process parameters. J Appl Polym Sci, 2008;108:4038-46.
20. Postlind H, Danielson A, Lindgren A, Andersson SH. A new muscarinic receptor antagonist is metabolized by cytochromes P450 2D6 and 3A in human liver microsomes. Drug Metab Dispos, 1998;26:289-93.
21. Schwach G, Oudry N, Delhomme S, Luck M, Lindner H, Gurny R. Biodegradable microparticles for sustained release of a new GnRH antagonist Y Part I: Screening commercial PLGA and formulation technologies. Eur J Pharm Biopharm, 2003;56:327-36.
22. Wischke C, Schwendeman SP. Principles of encapsulating hydrophobic drugs in PLA/PLGA microparticles. Int J Pharm, 2008;364:298-327.
23. Yang YY, Chung TS, Ng NP. Morphology, drug distribution, and in vitro release profiles of biodegradable polymeric microspheres containing protein fabricated by double emulsion solvent extraction/evaporation method. Biomaterials, 2001;22:231-41.
24. Zolnik BS, Burgess DJ. Evaluation of in vivo-in vitro release of dexamethasone from PLGA microspheres. J Controlled Release, 2008;127:137-45.